Erder, M Haim <br/><br/>
Cost effectiveness of guanfacine extended-release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder: application of a matching-adjusted indirect comparison.  [electronic resource] 

 -  Applied health economics and health policy  Nov 2012 
 - 381-95 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1179-1896 
<br/><br/><label>Standard No.: </label>10.1007/BF03261873  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adrenergic Uptake Inhibitors--economics<br/>Adrenergic alpha-2 Receptor Agonists--economics<br/>Atomoxetine Hydrochloride<br/>Attention Deficit Disorder with Hyperactivity--drug therapy<br/>Child<br/>Cost-Benefit Analysis<br/>Delayed-Action Preparations<br/>Female<br/>Guanfacine--economics<br/>Humans<br/>Male<br/>Markov Chains<br/>Propylamines--economics<br/>Quality-Adjusted Life Years<br/>Treatment Outcome